Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Change in Accured Expenses (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Change in Accured Expenses data on record, last reported at -$13.5 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 764.07% year-over-year to -$13.5 million; the TTM value through Dec 2025 reached -$4.6 million, up 80.51%, while the annual FY2025 figure was -$4.6 million, 80.51% up from the prior year.
  • Change in Accured Expenses reached -$13.5 million in Q4 2025 per MRVI's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $24.2 million in Q1 2023 and bottomed at -$24.1 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is -$398100.0, with a median of $1.5 million recorded in 2025.
  • Peak YoY movement for Change in Accured Expenses: surged 882.5% in 2022, then plummeted 870.77% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $7.5 million in 2021, then plummeted by 175.11% to -$5.6 million in 2022, then skyrocketed by 213.99% to $6.4 million in 2023, then crashed by 124.45% to -$1.6 million in 2024, then plummeted by 764.07% to -$13.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$13.5 million in Q4 2025, $1.5 million in Q3 2025, and $5.9 million in Q2 2025.